Tarsus CMO sells 13,953 shares at $85–$90
Tarsus Pharmaceuticals’ chief medical officer reported pre-planned open-market sales totaling 13,953 shares of TARS common stock.
Rhea-AI Filing Summary
Tarsus Pharmaceuticals, Inc. (TARS) reported that Chief Medical Officer Elizabeth Yeu Lin sold an aggregate of 13,953 shares of common stock on September 4, 2026. The sales included both directly held shares and shares held through a spouse’s Roth IRA, and were executed in the open market under pre-arranged Rule 10b5-1 trading plans adopted on May 29, 2026 and June 1, 2026. Following these transactions, an additional 12,040 shares of common stock are reported as indirectly held through a 401(k) plan.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Net Seller: 13,953 shares
Net Sell
5 txns
Insider
Lin Elizabeth Yeu
Role
Chief Medical Officer
Sold
13,953 shs ($1.22M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 5,387 | $85.00 | $458K |
| Sale | Common Stock F1 | 5,386 | $90.00 | $485K |
| Sale | Common Stock F2 | 1,590 | $85.00 | $135K |
| Sale | Common Stock F2 | 1,590 | $90.00 | $143K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 2,547 shares (Direct);
Common Stock — 1,590 shares (Indirect, By Spouse's Roth IRA);
Common Stock — 12,040 shares (Indirect, By 401(k) Plan)
Footnotes (2)
- F1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026.
- F2. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026.
Key Figures
Total shares sold: 13,953 shares
Direct sales at $85: 5,387 shares
Direct sales at $90: 5,386 shares
+5 more
8 metrics
Total shares sold
13,953 shares
Aggregate common stock sales reported for September 4, 2026
Direct sales at $85
5,387 shares
Directly held Tarsus Pharmaceuticals common stock sold at $85.00 per share
Direct sales at $90
5,386 shares
Directly held Tarsus Pharmaceuticals common stock sold at $90.00 per share
Spouse Roth IRA sales at $85
1,590 shares
Common stock sold from shares held through a spouse’s Roth IRA at $85.00 per share
Spouse Roth IRA sales at $90
1,590 shares
Common stock sold from shares held through a spouse’s Roth IRA at $90.00 per share
Indirect 401(k) holdings
12,040 shares
Common stock reported as indirectly held through a 401(k) plan after the transactions
Rule 10b5-1 plan adoption date
May 29, 2026
Adoption date for one of the trading plans covering the reported sales
Second Rule 10b5-1 plan adoption date
June 1, 2026
Adoption date for another trading plan covering the reported sales
Key Terms
Rule 10b5-1 trading plan, Roth IRA, 401(k) Plan
3 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Roth IRA financial
"By Spouse's Roth IRA"
A Roth IRA is a retirement savings account you fund with money that’s already been taxed, and withdrawals taken in retirement under the account rules are tax-free. It matters to investors because it shifts the tax bill to today instead of retirement, potentially increasing after-tax income later—think of it like paying for a lifetime subscription now so you can use it without extra charges in the future—helpful for long-term tax planning and flexibility.
401(k) Plan financial
"By 401(k) Plan"
A 401(k) plan is a workplace retirement account that lets employees set aside part of their pay into a tax-advantaged savings pot, often with employers adding matching contributions — like a workplace piggy bank for future income. It matters to investors because the amount people save and how employers fund these plans influence consumer spending, corporate payroll costs and the flow of money into financial markets, which can affect stock prices and company valuations.
FAQ
What insider transaction did TARS report for Chief Medical Officer Elizabeth Yeu Lin?
Tarsus Pharmaceuticals reported that Chief Medical Officer Elizabeth Yeu Lin sold 13,953 shares of common stock on September 4, 2026, through open-market transactions involving both directly held shares and shares held through a spouse’s Roth IRA.
Were the TARS insider sales made under a Rule 10b5-1 trading plan?
Yes. The footnotes state that the reported sales of Tarsus Pharmaceuticals common stock were effected under automatic sales pursuant to Rule 10b5-1 trading plans adopted by Elizabeth Yeu Lin on May 29, 2026 and June 1, 2026.
What TARS holdings are reported after the transactions in this Form 4?
After the reported sales, the Form 4 shows 12,040 shares of Tarsus Pharmaceuticals common stock held indirectly through a 401(k) plan. The filing does not state total remaining direct holdings for the reporting person.
AI-generated analysis. How Rhea-AI works. Not financial advice.
